Home › Trials › NCT05978141

Registry for individuals with T-cell lymphoma

The T-cell Lymphoma Master Repository (TCLMR): A Prospective Databank of Patients With T-cell Lymphoma With Clinical Annotation and Matched Tumor Specimens

Observational Memorial Sloan Kettering Cancer Center · NCT05978141

This study is gathering information from people with T-cell lymphoma to help researchers learn more about the disease and improve treatments.

Quick facts

Study typeObservational
Enrollment1000 (estimated)
SexAll
SponsorMemorial Sloan Kettering Cancer Center Academic / other
Locations26 sites (Duarte, California and 25 other locations)
Trial IDNCT05978141 on ClinicalTrials.gov

What this trial studies

This registry aims to create a comprehensive database to enhance the understanding of T-cell lymphoma and related conditions. By collecting information from participants, researchers will analyze data to identify patterns and improve treatment outcomes. The study involves optional blood and nail samples for further analysis. It focuses on various types of T-cell and NK-cell lymphomas, providing a platform for future research and clinical advancements.

Who should consider this trial

Good fit: Ideal candidates include individuals with pathologically-confirmed mature T-cell or NK-cell lymphoma.

Not a fit: Patients without a confirmed diagnosis of T-cell or NK-cell lymphoma may not benefit from this registry.

Why it matters

Potential benefit: If successful, this registry could lead to improved treatment strategies and outcomes for patients with T-cell lymphoma.

How similar studies have performed: Other registries and observational studies have shown success in improving understanding and treatment of similar hematological conditions.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Written informed consent
* Adequate fresh or archival tumor biopsy or intent to obtain fresh tumor biopsy.
* Pathologically-confirmed mature T- or natural killer (NK)-cell lymphoma meeting one of the following diagnostic criterion (based on WHO classification and NCCN guidelines):

  * T-cell prolymphocytic leukemia
  * T-cell large granular lymphocytic leukemia
  * Chronic lymphoproliferative disorder of NK cells
  * Aggressive NK-cell leukemia
  * Systemic Epstein-Barr virus (EBV)-positive T-cell lymphoma of childhood
  * Chronic active EBV infection of T- and NK-cell type, systemic form
  * Hydroa vacciniforme-like lymphoproliferative disorder
  * Adult T-cell leukemia/lymphoma
  * Extranodal NK/T-cell lymphoma, nasal type
  * Enteropathy-associated T-cell lymphoma
  * Monomorphic epitheliotropic intestinal T-cell lymphoma
  * Intestinal T-cell lymphoma, not otherwise specified (NOS)
  * Indolent T-cell lymphoproliferative disorder of the gastrointestinal tract
  * Hepatosplenic T-cell lymphoma
  * Subcutaneous panniculitis-like T-cell lymphoma
  * Mycosis fungoides (limited to those with ≥ stage IB disease and those receiving active therapy)
  * Sézary syndrome
  * Primary cutaneous anaplastic large cell lymphoma (receiving systemic therapy)
  * Primary cutaneous Gamma-Delta T-cell lymphoma
  * Primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma
  * Primary cutaneous acral CD8+ T-cell lymphoma (receiving systemic therapy)
  * Peripheral T-cell lymphoma, not otherwise specified
  * Angioimmunoblastic T-cell lymphoma
  * Follicular T-cell lymphoma
  * Nodal peripheral T-cell lymphoma with TFH phenotype
  * Anaplastic large cell lymphoma, ALK-positive
  * Anaplastic large cell lymphoma, ALK-negative
  * Breast-implant associated anaplastic large cell lymphoma.
* NOTE: Patients with diagnoses of mycosis fungoides, primary cutaneous anaplastic large cell lymphoma, and/or primary cutaneous acral CD8+ T-cell lymphoma must be receiving systemic therapy.

Exclusion Criteria:

* Patients with of mycosis fungoides, primary cutaneous anaplastic large cell lymphoma, and/or primary cutaneous acral CD8+ T-cell lymphoma not receiving systemic therapy.
* Inability to collect prospective data, measure response, or perform adequate follow-up assessments in the clinical judgment of the treating physician. NOTE: Repository participation does not exclude participation in clinical trials, nor does existing clinical trial participation exclude enrollment in the study herein outlined.

Where this trial is running

Duarte, California and 25 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions T-cell LymphomaNK-Cell LymphomaT-cell Prolymphocytic LeukemiaT-cell Large Granular Lymphocytic LeukemiaChronic Lymphoproliferative Disorder of NK CellsAggressive NK-cell LeukemiaSystemic Epstein-Barr Virus Positive T-Cell Lymphoproliferative Disease of ChildhoodSystemic Epstein Barr Virus Positive T-Cell Lymphoproliferative Disease of Childhood
Last reviewed 2026-06-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.